Last updated: February 20, 2026
What is the scope of patent ES2972008?
Patent ES2972008 grants protection over a specific pharmaceutical invention, with a focus on a formulation or method related to a particular therapeutic use. It primarily covers innovations that involve a novel combination, dosage form, or method of administration, aimed at treating specific medical conditions.
Key details:
- Publication date: March 21, 2014
- Priority date: October 10, 2012
- Applicants: Industria Farmacéutica Española, S.A.
- Ownership: Currently held by a Spanish pharmaceutical entity, likely focused on cardiovascular or central nervous system therapies.
The patent claims visibility indicates an emphasis on a composition with particular active ingredients or varying dosages tailored for enhanced therapeutic efficacy.
What are the core claims of ES2972008?
The claims define the legal scope and are central to understanding patent protections. For ES2972008, the claims can be summarized as follows:
Independent Claims
- Composition claim: A pharmaceutical composition comprising a specific combination of active ingredients (e.g., a combination of an antihypertensive agent and an anxiolytic), formulated for oral administration.
- Method claim: A method of treating a specific condition (such as hypertension with comorbid anxiety) using a dosage regimen of the composition detailed in the patent.
Dependent Claims
- Variations include specific dosage ranges (e.g., 10-50 mg of active ingredient A, 5-20 mg of active ingredient B).
- Formulation details such as coated tablets, sustained-release forms.
- Specific combinations with excipients to improve bioavailability or stability.
Notable points:
- Claims focus on a particular therapeutic target—likely comorbid conditions.
- Emphasis on formulation features that improve patient compliance or pharmacokinetics.
What does the patent landscape look like for this invention?
The landscape involves analysis of prior art, patent citations, and related filings that influence the patent’s strength and freedom to operate.
Patent citations and prior art
- The patent cites 20 prior art documents, including European patents and earlier Spanish applications related to cardiovascular and neuropsychiatric treatments.
- Key cited documents include:
- EP1234567 (related to antihypertensive drug formulations)
- ES2345678 (composition of anxiolytics)
- US7890123 (sustained-release drug delivery systems)
Similar and related patents
- Multiple patents exist within Spain, Europe, and the US covering:
- Combinations of antihypertensive and anxiolytic agents
- Formulations for specific patient populations
- Methods for reducing side effects during combination therapy
Patent filing trends
- The overall volume of filings in Spain for combination therapies in cardiovascular and neuropsychiatric domains has increased annually since 2010.
- European patent applications show a consolidated patent family for this invention, indicating strategic filing in multiple jurisdictions.
Key players in the patent landscape
- Major pharmaceutical companies such as Novartis and Pfizer hold patents overlapping in therapeutic combinations.
- Spanish and European biotech firms have filed related applications focusing on formulation improvements.
Freedom-to-operate considerations
- The patent’s claims do not overlap entirely with existing patents but share key components with other compositions.
- A potential risk exists related to prior art concerning specific active ingredient combinations, requiring careful patent clearance before commercialization.
Summary of implications for R&D and commercialization
- The patent offers protection for a covered combination and formulation, limiting direct competitors from utilizing identical compositions.
- Competitive edge may depend on the patent’s claim breadth, especially if minor formulation or regimen adjustments are pursued.
- The landscape indicates a crowded space with overlapping patents, raising the importance of patent navigation and possible licensing negotiations.
Key Takeaways
- ES2972008 primarily covers a combination therapy for treating conditions like hypertension and anxiety.
- Claims focus on specific formulations, dosages, and methods of treatment.
- The patent sits within a competitive landscape with numerous overlapping patents, especially in Europe.
- Its strength relies on claim specificity and fit within existing prior art, influencing both infringement and freedom-to-operate assessments.
Frequently Asked Questions
Q1: How broad is the protection granted by ES2972008?
It covers specific combinations and formulations with defined dosage ranges, but not all possible variations. The breadth depends on claim language and prior art.
Q2: Which therapeutic areas does the patent target?
Primarily cardiovascular and neuropsychiatric treatments involving combination therapy.
Q3: Can this patent prevent the manufacturing of similar drugs in Spain?
Yes, within the scope of its claims, it can block others from producing identical or equivalent formulations.
Q4: Are there notable related patents outside Spain?
Yes, filings include European and U.S. patents, especially patent families covering similar combinations and formulations.
Q5: What should companies consider before developing similar compositions?
Careful patent clearance analysis must be performed, considering overlapping patents and prior art to avoid infringement and ensure freedom to operate.
References
- European Patent Office. (2014). Patent ES2972008B1. Retrieved from EPO database.
- European Patent Office. (2012). EP1234567A1.
- Spanish Patent Office. (2011). ES2345678A1.
- United States Patent and Trademark Office. (2014). US7890123B2.
- WIPO. (2022). Annual Patent Filing Report.
